Insulin Resistance Lowers Odds of Hep C Treatment Success
People coinfected with both HIV and hepatitis C virus (HCV) are much less likely to respond to HCV treatment if they also have insulin resistance, according to a study published online June 25 in the Journal of Acquired Immune Deficiency Syndromes.
June 29, 2010
NIH Announces Grants to Search for HIV Cure The National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Mental Health (NIMH), both of the National Institutes of Health (NIH), have announced that a new pot of money will be made available to scientists who are searching for a cure for HIV.
June 28, 2010
Higher Mortality Risk in People With HIV-Related Inflammation
A new study suggests that people with HIV who have high blood levels of two inflammatory proteins—fibrinogen and C-reactive protein (CRP)—might have an increased risk of premature death. The study, published online June 25 in the Journal of Acquired Immune Deficiency Syndromes, found that the increased mortality risk was present even in people with high CD4 counts.
June 25, 2010
Levitra Doesn’t Increase “Dizzy Spells” in Selzentry Takers
People who are on a Selzentry (maraviroc) HIV regimen don’t have an increased risk for orthostatic hypotension—which can lead to a head rush or dizzy spell—if they take the erectile dysfunction (ED) drug Levitra (vardenafil). These results were published in the July 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
June 24, 2010
People Over 60 Respond Well to HIV Treatment
The vast majority of HIV-positive people older than 60 respond well to antiretroviral (ARV) therapy—achieving undetectable virus levels and substantial CD4 cell increases—according to a study published in the July 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
June 22, 2010
HIV-Related Kidney Troubles Linked to Age, Race, CD4 Count and Tenofovir
A new study has found that the overall rate of kidney dysfunction was only 3 percent in a group of HIV-positive military personnel, but several factors including older age, African-American race and the use of tenofovir (found in Viread, Truvada and Atripla) increased the risk of developing the condition. The study was published in the June issue of AIDS Patient Care and STDs.
June 21, 2010
Starting HIV Treatment Early Might Reduce Arterial Stiffness Initiating antiretroviral therapy when the CD4 cell count is above 350 is associated with a reduced risk of arterial stiffness, according to a University of California at San Francisco study published ahead of print online by the journal AIDS. Though the study’s design prevents drawing firm conclusions, the data may provide initial evidence that starting ARV treatment before CD4 cell counts drop may be a way to reduce cardiovascular disease risk among people living with HIV
June 17, 2010
Novel Anti-HIV Gene Therapy Demonstrates Glimmers of Success The molecular pieces of an anti-HIV gene therapy—when given to HIV-positive people with lymphoma—persist in the blood for up to two years post-infusion, according to a study announced by researchers at City of Hope hospital in Duarte, California, and published June 16 in Science Translational Medicine. Though the experiment doesn’t prove that the new gene therapy can cure HIV, it does demonstrate that it’s safe and that the body doesn’t reject the treatment.
June 15, 2010
A Slower Response to HIV Treatment Is Just as Good as a Fast Response People whose HIV levels drop more slowly after starting antiretroviral (ARV) therapy do just as well over two years as people whose virus drops rapidly, according to a research letter published in the June 19 issue of AIDS. These data potentially refute a long-standing theory that viral loads should decrease quickly during the initial months of treatment to maximize the chances of long-term success on a particular drug regimen.
June 14, 2010
NRTI Resistance May Blunt PI-to-Isentress Switch Effectiveness HIV-positive individuals with a history of nucleoside reverse transcriptase inhibitor (NRTI) resistance may be more likely to experience viral load rebounds upon switching to Isentress (raltegravir) from a protease inhibitor (PI), according to new data reported at the International HIV and Hepatitis Drug Resistance Workshop earlier this month in Dubrovnik, Croatia.
June 11, 2010
New Role for HIV Protease Inhibitors?
At least two protease inhibitors (PIs)—Norvir (ritonavir) and Invirase (saquinavir)—might offer additional health benefits beyond their direct virus-fighting ability, according to a study published June 10 in PLoS Medicine. Should other studies confirm this finding, it could affect how current protease inhibitors are used and prompt new research on this class of drugs.
Genital Warts Should Be Tested for Cancerous Cells
Anal warts in men who have sex with men (MSM) often contain cancerous and precancerous cells, an “unsettling” finding of a study reported in the July 1 issue of Clinical Infectious Diseases. The authors indicate that simply treating anal warts isn’t enough among MSM—they should be surgically removed and tested for high-grade cells that can potentially cause serious disease.
Medicare Codes for Facial Fillers Now Available Healthcare Common Procedure Coding System (HCPCS) numbers have been assigned to two facial fillers for HIV-related lipoatrophy, which should make it easier for patients covered by Medicare to receive treatment. The new HCPCS codes were announced in an update from the Department of Health and Human Services (DHHS) Centers for Medicare & Medicaid Services (CMS) published May 21.
June 03, 2010
HIV-Positive Women Are Not Getting Pregnancy Counseling More than half of HIV-positive women who wish to have children have not received adequate pregnancy counseling from their health care providers, according to a study published in the May 20 issue of AIDS Patient Care and STDs.